AstraZeneca Crestor
Executive Summary
AstraZeneca cholesterol agent Crestor (rosuvastatin) has a user fee action deadline in August, after the company submitted additional data on 10 mg to 40 mg doses to FDA Feb. 12. AstraZeneca received an "approvable" letter for Crestor May 31, 2002 (1"The Pink Sheet" June 10, 2002, In Brief)...
You may also be interested in...
AstraZeneca Crestor is “approvable”
AstraZeneca receives "approvable" letter for Crestor (rosuvastatin) May 31, a month ahead of the 12-month review deadline. The company expected an "approvable" letter from FDA for the statin, whose 80 mg dose has been associated with rhabdomyolysis (1"The Pink Sheet" Feb. 4, p. 25)...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.